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Sequence analysis identified significant variation in the second exon of equine infectious anemia virus
(EIAV) rev. Functional analysis indicated that limited amino acid variation in Rev significantly altered the
export activity of the protein but did not affect Rev-dependent alternative splicing. EIAV Rev can mediate
export through two independent cis-acting Rev-responsive elements (RREs), and differences among Rev
variants were more pronounced when both RREs were present. Variation in Rev may be an important
mechanism for regulation of virus replication in vivo and may contribute to changes in clinical disease.
Equine infectious anemia virus (EIAV) is a member of the
lentivirus subfamily of retroviruses and possesses many of the
characteristic features of that subfamily including a complex
genome organization, tropism for cells of the monocyte/mac-
rophage lineage, and establishment of a persistent, lifelong
infection. Whereas lentivirus infections are typically character-
ized by a slow, chronic disease, EIAV can induce a rapid,
variable disease course in horses. Horses which survive early
clinical episodes carry a lifelong, persistent infection with low
viral load. The rapid changes between clinical stages of disease
which occur during EIAV infection provide for an excellent
model for analyzing factors which contribute to lentivirus
pathogenesis and persistence. One factor important in EIAV
persistence and pathogenesis is genetic and antigenic variation.
Genetic mutations in the viral env gene are associated with the
occurrence of antigenic-variant viruses, and the role of anti-
genic variation in EIAV persistence has been extensively stud-
ied (14, 20, 29, 32, 35). Additional clusters of genetic variation
are found in the virus long terminal repeat and in the region of
gp45/Rev overlap (1, 4, 21, 27). The biological significance of
variation in these regions is not clear; however, genetic changes
which alter levels of viral gene expression may be important
factors in viral pathogenesis in vivo. EIAV replicates in cells of
the monocyte/macrophage lineage (28), and the severity of
clinical and pathological signs of disease is closely associated
with levels of viral replication in these cells (3). Therefore,
variation in viral regulatory elements may modulate overall
levels of virus replication and contribute to changes in clinical
disease course.
Lentiviruses utilize complex mechanisms to regulate virus
replication. The regulatory protein Rev functions to direct the
nuclear export of incompletely spliced viral RNAs encoding
viral structural proteins during the late phase of virus replica-
tion. Numerous lentiviruses utilize Rev-dependent RNA ex-
port pathways (reviewed in reference 9), and the human im-
munodeficiency virus type 1 (HIV-1) Rev-mediated RNA
export pathway is the best-characterized pathway. HIV-1 Rev
binds a secondary structure in the viral pre-mRNA called the
Rev-responsive element (RRE) (8, 24, 42), multimerizes (22,
23, 34, 41), and then utilizes a non-mRNA nuclear export
pathway to redirect movement of incompletely spliced RNA
from the nucleus (2, 10, 11, 40). Discrete functional domains
within the protein mediate the interactions of Rev with cellular
proteins and viral RNA required for nuclear localization, RNA
binding, multimerization, and nuclear export.
EIAV Rev is a 165-amino-acid protein translated from a
bicistronic four-exon mRNA coding for both Tat and Rev (7,
39). The nuclear export signal (NES) of EIAV Rev has been
mapped to amino acids 31 to 55 (12), and domain swapping
experiments have shown that the EIAV Rev NES can substi-
tute for the HIV-1 or visna virus NES (2, 25, 30). Other
functional domains of EIAV Rev have not yet been identified.
EIAV Rev also has an additional, apparently unique function
among complex retrovirus export proteins. Whereas HIV-1
Rev and human T-cell leukemia virus type 1 Rex inhibit the
expression of both Tat- and Rev-specific mRNAs in facilitating
the export of incompletely spliced mRNAs, EIAV Rev specif-
ically down-regulates its own production, independent of Tat,
by promoting exon 3 skipping of the bicistronic mRNA (Fig. 1)
(13, 26). This mechanism allows for continuous production of
Tat, while Rev synthesis is limited. Although the mechanism by
which the alternative splicing occurs has yet to be completely
delineated, it has been proposed that binding of EIAV Rev to
an RRE overlapping exon 3 interferes with SR protein-RNA
or SR protein-snRNP interactions (13). The disruption of SR
protein binding is thought to result in exon 3 exclusion (13).
This multifunctional nature of EIAV Rev highlights its impor-
tance in regulation of virus gene expression and replication. As
such, genetic variation in Rev may have added significance in
vivo.
Rev is absolutely required for expression of lentivirus struc-
tural genes and production of new virus. Therefore, factors
which modulate Rev activity and, consequently, alter levels of
viral gene expression may be important in regulating virus
replication in vivo. Rev-attenuated phenotypes have been
identified during asymptomatic stages of HIV-1 infection, sug-
gesting that variation in Rev could alter virus replication in
vivo and contribute to the clinical outcome of infection (16,
18). It would be expected that viral phenotypes that included
highly competent Rev phenotypes would be present during
periods of rapid virus replication, whereas the production of
“attenuated” or latent virus may be important for evasion of an
active host immune response during periods of long-term per-
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sistence. Indeed, using multiple assays Hua et al. (16) showed
that HIV-1 Rev clones obtained from asymptomatic infections
were less functional than wild-type Rev. Restricted expression
of viral structural genes is a common strategy of persistent
viruses (33), and these findings suggest that variation in Rev
may be an important factor in lentivirus pathogenesis. We had
previously identified extensive nucleotide substitutions in the
Rev open reading frame (ORF) from virus obtained from a
horse experimentally infected with EIAV (1). The coexistence
of putative Rev-competent and Rev-deficient phenotypes sug-
gested that variation in EIAV Rev may contribute to virus
persistence through regulation of structural gene expression.
The goal of the present study was to further characterize ge-
netic variation in EIAV Rev and to determine if variation in
EIAV Rev altered biological activity.
Genetic variation in EIAV Rev. To further explore the po-
tential role of Rev variation in EIAV pathogenesis, we ana-
lyzed Rev cDNAs obtained from cells inoculated with either
FIG. 1. Organization of the EIAV genome. (A) Known ORFs and predominant mRNAs isolated from virus-infected tissue culture cells (19). LTR, long terminal
repeat. (B) Location of EIAV regions inserted into pDM138 CAT constructs (17). pERRE-All contains nucleotides 5280 to 7534, pERRE-1 contains a short 59 RRE
sequence overlapping the first Rev exon (nucleotides 5280 to 5834), and pERRE-2 contains a major portion of the remaining downstream EIAV sequence present in
pERRE-All (nucleotides 5837 to 7534) (15). All numbering of nucleotides in the present report is based on that of Kawakami et al. (19).
FIG. 2. Amino acid sequence alignments of the product of Rev exon 2 (amino acids 31 to 165). (A) Amino acid sequence of the product of exon 2 of MA-1 Rev
(4) and amino acid sequences encoded by cDNAs isolated from MA-1-infected ED cells (ME) and MA-1-infected horse macrophage cultures (HMC) (MM). (B)
Amino acid sequences of products of cDNAs isolated from Th-1-infected HMC (A22, B11, F22, H21) and viral DNAs isolated from an EIAV-positive horse at the
first and sixth febrile cycles (Th-1 and Th-6, respectively) (1). Missing sequences are due to the use of an internal 59 primer for PCR amplification. (C) Amino acid
sequences deduced from in vivo Rev exon 2 sequences obtained from GenBank (accession no. X63059, X16988, M14855, M18385, M18386, M18387, M18388, M87580,
and M93674).
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the Th-1, Th-6, or MA-1 virus isolate (Fig. 2A and B), as well
as additional EIAV Rev sequences available in GenBank (Fig.
2C). Th-1 and Th-6 are field-derived virus isolates of EIAV
recovered during the first and sixth febrile cycles, respectively,
of a horse experimentally inoculated with whole blood from an
EIAV-seropositive, naturally infected horse (1, 6). MA-1 is a
cell culture-adapted, avirulent virus derived from Th-1 by in
vitro passage in equine dermal (ED) cells (5, 6). The analysis
indicated a high degree of genetic variation in Rev exon 2. The
sequences represent those from a variety of isolates, including
virulent (Wyoming) and avirulent (MA-1) EIAV as well as in
vivo- (Th-1, Th-6) and in vitro-adapted (MA-1) virus. Some of
the sequences were derived from a single proviral clone iso-
lated by limiting dilution and thus are representative of a
predominant virus (i.e., P3.21), whereas other sequences rep-
resent quasispecies obtained following PCR amplification and
cloning of viral cDNA or proviral DNA (Th-1.51). Numerous
amino acid substitutions were found in the NES and in a
71-amino-acid region encoded by the center portion of the
exon. The changes included deletions as well as amino acid
substitutions, some of which were associated with the appear-
ance of premature stop codons. In many cases, identical sub-
stitutions were found to reoccur or to occur at specific amino
acids, regardless of the virus isolate. Examples include valine/
alanine at amino acid 105 and isoleucine/arginine/asparagine
at amino acid 113. In other cases, a single change was diag-
nostic of a particular virus isolate. For example, all of the
MA-1 quasispecies contained a glycine at amino acid 39,
whereas cDNA clones from the related Th-1 virus or the un-
related Wyoming strain of virus encode an aspartic acid at that
location. Also, the glutamine and serine amino acids present at
positions 134 and 135, respectively, were more frequent in
MA-1 quasispecies, whereas the glycine-to-aspartic acid
change at amino acid 115 was found only in the virulent Wy-
oming strain of EIAV. Within the NES, 80% of the variation
occurred at amino acids reported to be necessary for Rev
activity (25). While it is possible that the observed variation in
Rev is merely a consequence of random variation or that it
reflects selection for changes in the overlapping gp45 reading
frame, recent findings suggest a role for Rev variation in the
biology of EIAV in vivo. During successive febrile periods in a
pony experimentally inoculated with EIAV, nucleotide and
amino acid variation in EIAV Rev accumulated at approxi-
mately the same rate as that observed in gp90 and more fre-
quently than was observed in gp45 or in the long terminal
repeat (31). Taken together, these findings support the hypoth-
esis that variation in EIAV Rev is biologically significant.
Two independent RREs can mediate EIAV Rev-dependent
export. To assess the functional activity of Rev variants, we
developed an in vitro nuclear export assay similar to that
widely used in functional assays of other lentivirus Rev pro-
teins (17, 25, 37). In other complex retroviruses, transactiva-
tion of the Rev/Rex RNA export pathway occurs through an
interaction with a single RRE (reviewed in reference 9). For
the majority of lentiviruses, the RRE is located near the sur-
face transmembrane envelope region; two exceptions are feline
immunodeficiency virus and human T-cell leukemia virus type
1, for which the RREs have been mapped near the 39 end of
the genome (9, 36, 38). Surprisingly, previous studies have
identified two cis-acting regions in EIAV which are able to act
as RREs (15, 26). However, the specific binding of Rev with
only one element overlapping the 39 end of the first rev exon
has been shown (13). The exact location of the second RRE
has not been identified, and initial studies were performed to
confirm the presence of two RREs. A pDM138-derived re-
porter plasmid, pERRE-All, was constructed which has the
chloramphenicol acetyltransferase (CAT) gene and a region
containing all of the putative EIAV RRE sequences within an
intron flanked by HIV-1 splice sites (15, 17). Additional re-
porter plasmids containing EIAV regions previously shown to
be able to act as RREs were constructed (26): pERRE-1 con-
tains a short 59 RRE sequence overlapping the first Rev exon,
and pERRE-2 contains a major portion of the remaining
downstream EIAV sequence present in pERRE-All (15). The
locations of the EIAV sequence present in the reporter con-
structs are shown in Fig. 1B. For functional assays, 293 cells
were seeded in triplicate at 1 3 105 to 5 3 105 cells/well in
six-well tissue culture dishes. The next day cells were trans-
fected with 0.2 mg of reporter plasmid, 0.2 mg of beta-galacto-
sidase reporter plasmid pCH110 (Pharmacia, Uppsala, Swe-
den) or pSV–beta-galactosidase (Promega, Madison, Wis.),
and 1 mg of an MA-1 Rev expression plasmid or empty vector.
pUC19 DNA was added to bring the total amount of DNA
transfected in each well to 2 mg. Cells were transfected by
calcium phosphate coprecipitation, and the medium was
changed the next day. Two days posttransfection cells were
harvested in phosphate-buffered saline containing 5 mM
EDTA, pelleted, resuspended in 300 ml of 0.25 M Tris, pH 7.5,
and lysed by three rounds of freezing and thawing. Fifty mi-
croliters of lysate was assayed for beta-galactosidase activity,
and these values were used to normalize lysates for CAT as-
says. Reaction mixtures for CAT assays were equalized with
0.25 M Tris, pH 7.5, to a final volume of 92 ml and incubated
at 37°C with 5 ml of 20 mM acetyl coenzyme A and 3 ml of
[14C]chloramphenicol (50 mCi/mmol). Unacetylated and
acetylated forms were separated by thin-layer chromatography
and quantified with a Molecular Dynamics phosphorImager
(Sunnyvale, Calif.). The percentage of acetylation was calcu-
lated for each transfection, and the data represents the average
acetylation and standard error of the mean for all experiments.
All three ERRE reporter plasmids were found to contain
cis-acting elements able to mediate Rev-dependent RNA ex-
port (Fig. 3A). For purposes of comparison, results are pre-
sented as percentages of activity found with pERRE-All, which
is shown as 100%. pERRE-1, containing the RNA element
shown by Gontarek and Derse to interact with glutathione
S-transferase–Rev in vitro (13), produced the majority (52%)
of activity found with pERRE-All. In contrast, assays with
pERRE-2 resulted in only 17% of the activity seen with the
pERRE-All vector. There was also a low level of transactiva-
tion of the background vector, pDM138. These findings con-
firm previous studies indicating that EIAV Rev can mediate
nuclear export through two separate RREs (26). In addition,
they provide quantitative results which indicate that the pri-
mary RRE is contained within ERRE-1 and encompasses Rev
exon 1. Although both RREs appear to be required for max-
imum efficiency of the Rev-dependent export pathway, the
significance of ERRE-2 as an important mediator of RNA
export is questionable. The results presented here suggest that
ERRE-2 functions primarily as an enhancer of ERRE-1 rather
than as an independent mediator of RNA export. Further
studies are needed to more clearly ascertain the mechanism of
the EIAV dual-RRE export pathway.
Variation in Rev alters biological activity. To determine
whether amino acid variation in Rev resulted in differences in
biological activity, eight variant Rev cDNAs, four from MA-1-
infected ED cells and four from Th-1-infected macrophages,
were cloned into the eukaryotic expression vector pCR3 (In-
vitrogen, Carlsbad, Calif.) for functional analysis. Western blot
analysis with Rev-specific polyclonal antibodies confirmed that
all variants were expressed at similar levels (data not shown).
Variant cDNAs were assayed in transient-expression assays by
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cotransfection with Rev reporter plasmids containing ERRE-
All, ERRE-1, or ERRE-2 as described above. The results
indicated that amino acid changes encoded by the Rev ORF
significantly altered biological activity (P , 0.0001) when both
RREs were present (Fig. 3B). Variants ranged from being
inactive (A22) to producing activities greater than threefold
that of MA-1 Rev (H21). EIAV Rev variants F22, H21, and
27D4 were significantly more active than all other variants. In
general, the range of biological variation was greater in the
Th-1-derived Revs, consistent with the greater degree of se-
quence diversity of those clones compared to that of the MA-
1-derived clones. The results are consistent with studies ana-
lyzing variation in HIV-1 Rev (16) and support the hypothesis
that biological changes in Rev activity may have significance in
vivo. In addition, our results demonstrate that variation in
regions outside the NES can also alter nuclear export activity.
Because all assays were done with a single RRE sequence, we
cannot rule out the possibility that compensatory mutations in
the RRE minimize the biological effects of Rev variation in
vivo. Such analysis requires further mapping of the EIAV
RREs.
Given the possibility of a synergistic interaction contributing
to EIAV Rev-dependent export, we further characterized the
effects of variation with the individual RREs by assaying the
nine variants with both pERRE-1 and pERRE-2. Since the
functional activities of the reporter plasmids differ (Fig. 3A),
the experiments with the separate reporter plasmids were per-
formed under CAT assay conditions in which the acetylation of
pcMARev lysates was approximately 20%. An analysis of the
individual Rev variants with the pERRE-1 reporter plasmid
produced a pattern of activity relative to MA-1 Rev similar to
that observed with ERRE-All (Fig. 3B and C). However, with
the exception of A22, the differences among the variants were
less pronounced than those observed with the pERRE-All
reporter plasmid. H21 was only twofold more active than
MA-1 Rev, while 27A2 and 27D2 were slightly more active
than MA-1 Rev. Surprisingly, the pattern of variation seen with
pERRE-All was abolished when the variants were assayed with
the pERRE-2 reporter plasmid (Fig. 3D). A22 was still inac-
tive, but all other variants were more active than MA-1 Rev
and not significantly different from each other. Together, these
results indicate that genetic variation in Rev alters biological
activity and that the effects of Rev variation are enhanced in
the presence of both RREs. The mechanism(s) by which EIAV
Rev utilizes two separate RREs is unknown, and it is not clear
why the differences among the variants are decreased when
only one RRE is present. As suggested above, the downstream
RRE may function primarily as an enhancer element of nu-
clear export mediated by RRE-1. If so, the effects of variation
in regions of Rev important for interaction between RRE-1
and RRE-2 may require the presence of both elements for
observable differences in biological activity.
Rev-dependent alternative splicing is not affected by varia-
tion. The current model of EIAV Rev-dependent alternative
splicing proposes that the binding of Rev to ERRE-1 interferes
with SR protein-RNA or SR protein-snRNP interactions to
promote exon 3 skipping (13). The significance of this phe-
nomenon in terms of virus replication is not known, although
alternative splicing may play an important role in regulation of
virus replication. Therefore, studies were undertaken to deter-
mine if the Rev sequence variants differed in splice site utili-
zation during EIAV mRNA processing. To analyze Rev-me-
diated alternative splicing patterns, we developed Cf2Th cell
lines stably transfected with a Rev-defective (Cf2th/51) or Rev-
FIG. 3. In vitro assays of EIAV Rev activity. Transfection experiments were performed as described in the text. Two days posttransfection cells were harvested and
lysates were normalized for the CAT reactions by a beta-galactosidase assay. Individual experiments included triplicate wells, and the data shown represents the means
of at least three separate experiments. Error bars denote the standard errors of the means for all experiments. (A) Rev can trans activate through two discrete regions
of EIAV. pcMARev transactivation of CAT reporter plasmids pERRE-All, pERRE-1, pERRE-2, and pDM138 is shown. Each reporter plasmid contains the EIAV
sequences shown in Fig. 1B; pDM138 is the background reporter plasmid. Transfections and CAT assays were performed as described in the text, except that lysates
from wells with pERRE-All were diluted fivefold to allow for the comparison. (B) Transactivation of pDM138 CAT reporter plasmid pERRE-All by EIAV Rev variants
showing that amino acid variation in Rev alters the biological activity of the protein. (C and D) Transactivation of pDM138 CAT reporter plasmids pERRE-1 (C) and
pERRE-2 (D) by EIAV Rev variants indicating that the full effects of variation require both RRE regions. CAT assays were performed for each experiment under
conditions that resulted in approximately 20% acetylation for the pcMARev lysates. Therefore, although the activities of the reporter plasmids differ, all experiments
appear on the same scale.
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competent (Cf2th/112) provirus by G418 selection (data not
shown). Cf2Th/51 cells were then trans-complemented with the
variant cDNAs. Cells were seeded at 2 3 105 cells/well in
six-well tissue culture plates and transfected with 9 mg of Rev
variant plasmid or empty-vector DNA by liposome-mediated
transfection (Boehringer Manneheim, Indianapolis, Ind.). Two
days posttransfection, RNA was isolated and cDNAs were
amplified by reverse transcription-PCR (RT-PCR) using prim-
ers which spanned all EIAV splice donor and splice acceptor
sites (59 primer: CGCAGACCCTACCTGTTG [nucleotide
354]; 39 primer: TCTTCAGGTAACGACTGCC [nucleotide
7301]). To allow for sensitive visualization of the splicing prod-
ucts, the 59 primer was end labeled with 32P. RT-PCR was
performed as described by the manufacturer (Perkin-Elmer,
Foster City, Calif.). PCR was performed at an annealing tem-
perature of 55°C and run for 25 cycles. DNA from the RT-PCR
reactions was phenol-chloroform extracted, ethanol precipi-
tated, and resuspended in 40 ml of 0.13 Tris-EDTA buffer.
Ten microliters of each reaction mixture was electrophoresed
through a denaturing (7 M urea) 5% polyacrylamide gel. Gels
were fixed, dried, and then exposed to film for visualization. As
a control, Rev mRNAs were amplified from transfected plas-
mids with pCR3-specific primers (59 primer: ATACGACTCA
CTATAGGG; 39 primer: ATTTAGGTGACACTATAG).
The results indicated that both the 1,2,3,4 exon mRNA and the
alternately spliced 1,2,4 exon mRNA were present in Cf2th/112
cells and in all Cf2th/51 cells trans-complemented with variant-
Rev cDNAs, including that of the functionally inactive A22
(Fig. 4). In contrast, the 1,2,4 exon mRNA was not detected in
Cf2Th/51 cells alone or in cells trans-complemented with vec-
tor DNA. The failure to detect differences in alternative splic-
ing patterns suggests that variation present in the cDNAs we
examined is not important for Rev-mediated alternative splic-
ing. The finding that A22 was similar to the products of other
variant cDNAs in splice site utilization indicates that the nu-
clear export function of Rev is independent of exon 3 skipping.
Therefore, these two functions most likely occupy separate
domains in the protein, although both functions may require
RRE binding.
Overall, our findings demonstrate that variation can enhance
or attenuate the EIAV Rev phenotype. Previous studies with
HIV-1 have shown that variation within the HIV-1 Rev NES
can alter the biological phenotype and that the observed
changes in function were consistent in both in vitro assays and
studies of virus replication (16). We have demonstrated that
variation in regions other than the NES can also modulate Rev
activity in vitro. Given the extent of Rev variation we have
observed, our results suggest that variation in Rev may be an
important mechanism for modulating levels of virus replication
during the course of clinical disease. Indeed, Leroux et al.
reported rapid variation in Rev during sequential febrile cycles
of a pony experimentally inoculated with EIAV (21). Func-
tional Rev is absolutely required for production of infectious
virus, and it might be expected that Rev-defective or Rev-
attenuated genotypes would be rapidly selected against during
replication in vivo. However, factors which decrease Rev ac-
tivity and decrease levels of viral gene expression may have a
selective advantage and allow virus to persist in the face of an
active host immune response. Further structural and functional
analysis of in vivo-derived variants at different stages of the
clinical disease course are needed to delineate the role of Rev
in lentivirus pathogenesis.
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